Skip to main content

Advertisement

SpringerLink
Log in

Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to compare the efficacies and safeties of the combination of docetaxel-carboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian, primary peritoneal or fallopian tube cancers.

Methods

Relevant articles were identified from MEDLINE (1993–2010), EMBASE (1980–2010), MEDION, the Cochrane library, Science Citation Index Expanded databases, hand searching of reference lists from primary articles and reviews, conference abstracts and contact with experts in the field. The review included 5 relevant primary studies (1430 women). Data was extracted for study characteristics and quality. Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.

Results

The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxel-carboplatin group (OR = 1.33, 95% CI = 1.13–1.56, P = 0.0005), whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin (OR = 1.0, 95% CI = 0.87–1.16, P = 0.95). There were heterogeneity (χ2 = 79.36, P < 0.00001) and inconsistency (83.6%) in toxicity analysis among the trials, while neither heterogeneity (χ2 = 3.21, P = 0.99) nor inconsistency (I 2 = 0%) in clinical responses among the trials.

Conclusion

The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin. However, the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Decker DG, Fleming TR, Malkasian GD Jr, et al. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol, 1982, 60: 481–487.

    CAS  PubMed  Google Scholar 

  2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med, 1996, 334: 1–6.

    Article  CAS  PubMed  Google Scholar 

  3. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst, 2000, 92: 699–708.

    Article  CAS  PubMed  Google Scholar 

  4. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003, 21: 3194–3200.

    Article  CAS  PubMed  Google Scholar 

  5. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst, 2003, 95: 1320–1329.

    PubMed  Google Scholar 

  6. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol, 2000, 18: 3084–3092.

    CAS  PubMed  Google Scholar 

  7. Gu MJ, Shi W. Current research and management of ovarian cancer in China. Chinese-German J Clin Oncol, 2002, 1: 212–218.

    Article  Google Scholar 

  8. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst, 2004, 96: 1682–1691.

    Article  CAS  PubMed  Google Scholar 

  9. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol, 2004, 27: 14–18.

    Article  CAS  PubMed  Google Scholar 

  10. Minagawa Y, Kigawa J, Kanamori Y, et al. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol, 2006, 101: 495–498.

    Article  CAS  PubMed  Google Scholar 

  11. Mori T, Hosokawa K, Kinoshita Y, et al. A pilot study of docetaxelcarboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol, 2007, 12: 205–211.

    Article  CAS  PubMed  Google Scholar 

  12. Markman J, Zanotti K, Webster K, et al. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol, 2004, 92: 592–595.

    Article  CAS  PubMed  Google Scholar 

  13. Guastalla JP, Pujade-Lauraine E, Weber B, et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens) phase II study. Ann Oncol, 1998, 9: 37–43.

    Article  CAS  PubMed  Google Scholar 

  14. McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer, 2003, 89 Suppl 3: S3–8.

    Article  Google Scholar 

  15. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer — an updated overview. Eur J Cancer, 1997, 33: 2167–2170.

    Article  CAS  PubMed  Google Scholar 

  16. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol, 2007, 14: 195–208.

    Article  CAS  PubMed  Google Scholar 

  17. Misawa H, Ochiai K, Yasuda M, et al. Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer. Nippon Rinsho (Japanese), 2004, 62Suppl 10: 546–549.

    Google Scholar 

  18. Furugen Y, Nishihara S, Kurokawa A, et al. Combination chemotherapy with docetaxel + carboplatin in the treatment of cancer of the ovary and fallopian tube. Gan To Kagaku Ryoho (Japanese), 2004, 31: 1205–1208.

    Google Scholar 

  19. Pfisterer J, du Bois A, Wagner U, et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol Oncol, 2004, 92: 949–956.

    Article  CAS  PubMed  Google Scholar 

  20. Vasey PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer, 2001, 84: 170–178.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Tianjin Central Gynecology & Obstetric Hospital, Tianjin, 300052, China

    Hongxiao Chen, Yang Rao & Pengpeng Qu

Authors
  1. Hongxiao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pengpeng Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pengpeng Qu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, H., Rao, Y. & Qu, P. Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis. Chin. -Ger. J. Clin. Oncol. 9, 475–481 (2010). https://doi.org/10.1007/s10330-010-0652-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-010-0652-z

Key words

Search

Navigation